skip to content

Market News

Broker views: Pharma and banking

17 May 2017 15:44

Jefferies has double downgraded its investment rating on Hikma Pharmaceuticals (LON:HIK) and moved straight to underperform from buy, stating that US Generics Advair delay a significant setback.

The broker added: "We expect a cautious IMS on May 19. Although momentum in injectables remains robust, we believe the delay is likely to act as a serious drag to sentiment until the US business turns around; hence our double downgrade."

Jefferies lowered its price target to 1,450p per share from 2,162p.

Meanwhile, Credit Suisse upgraded its recommendation on Virgin Money (LON:VM.) to outperform (from neutral), believing concerns about the credit card business, causing the recent underperformance, are overdone.

Nevertheless, analysts left their target price unchanged at 345p per share.

At 3:44pm:

(LON:HIK) Hikma Pharmaceuticals PLC share price was -53.5p at 1712.5p

(LON:VM.) Virgin Money Holdings UK Plc share price was -0.85p at 305.15p

Story provided by StockMarketWire.com

Related Company: HIK

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

Bluezest Aberdeen

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.